MA48461A - Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation - Google Patents

Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation

Info

Publication number
MA48461A
MA48461A MA048461A MA48461A MA48461A MA 48461 A MA48461 A MA 48461A MA 048461 A MA048461 A MA 048461A MA 48461 A MA48461 A MA 48461A MA 48461 A MA48461 A MA 48461A
Authority
MA
Morocco
Prior art keywords
excipients
viscosity
reduce
antibody formulations
formulation compositions
Prior art date
Application number
MA048461A
Other languages
English (en)
Inventor
Robert Matthew Fesinmeyer
Jian Hua Gu
Rulin Qian
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA48461A publication Critical patent/MA48461A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MA048461A 2017-04-28 2018-04-24 Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation MA48461A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762492049P 2017-04-28 2017-04-28

Publications (1)

Publication Number Publication Date
MA48461A true MA48461A (fr) 2020-03-04

Family

ID=62148500

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048461A MA48461A (fr) 2017-04-28 2018-04-24 Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation

Country Status (4)

Country Link
US (2) US12257343B2 (fr)
EP (1) EP3615065A1 (fr)
MA (1) MA48461A (fr)
WO (1) WO2018200533A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109439536A (zh) * 2017-08-18 2019-03-08 黄国仁 饮用水细菌快速培养装置及菌落总数快速检测系统
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
WO2020205716A1 (fr) * 2019-04-01 2020-10-08 Genentech, Inc. Compositions et procédés de stabilisation de formulations contenant des protéines
CN113660927A (zh) 2019-04-23 2021-11-16 安进公司 使用低分子量聚乙烯吡咯烷酮（pvp）降低高浓度蛋白质配制品的黏度
WO2021030179A1 (fr) * 2019-08-12 2021-02-18 Amgen Inc. Formulations d'anticorps anti-sclérostine
CA3163358A1 (fr) 2019-12-03 2021-06-10 Evotec International Gmbh Proteines de liaison a l'antigene associees a l'interferon et leurs utilisations
CR20220457A (es) * 2020-02-13 2023-01-09 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria
MX2022010120A (es) * 2020-02-18 2022-09-05 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos.
CA3187322A1 (fr) * 2020-07-13 2022-01-20 Merck Patent Gmbh Excipients reducteurs de viscosite et leurs combinaisons pour formulations de proteines hautement concentrees
WO2023140807A1 (fr) * 2022-01-19 2023-07-27 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions pharmaceutiques de trastuzumab
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
WO2026006472A2 (fr) 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Compositions d'anticorps il-1r1 et leurs procédés de production et d'utilisation
WO2026003765A1 (fr) 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Formulations d'anticorps anti-récepteur 1 de l'interleukine 1

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
EP1690935A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
WO2004039337A2 (fr) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Formulations pharmaceutiques liquides stables d'anticorps ayant tendance a l'isomerisation
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
EP2129401B8 (fr) 2006-12-21 2020-01-15 Amgen Inc. Formulations tamponnées stables contenant des polypeptides
JP5419709B2 (ja) 2007-01-09 2014-02-19 ワイス・エルエルシー 抗ｉｌ−１３抗体製剤およびその使用
KR101540823B1 (ko) 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
BR112012027828A2 (pt) * 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
RU2614257C2 (ru) * 2011-04-20 2017-03-24 Сандоз Аг СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ СЛИТОГО БЕЛКА TNFR:Fc
AU2012328524B2 (en) 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
WO2015196091A1 (fr) 2014-06-20 2015-12-23 Reform Biologics, Llc Composés excipient réduisant la viscosité pour formulations à base de protéines
US20170198059A1 (en) * 2014-07-14 2017-07-13 Amgen Inc. Crystalline antibody formulations
ES2964713T3 (es) 2014-10-23 2024-04-09 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
PL3615066T3 (pl) * 2017-04-28 2024-04-29 Amgen Inc. Formulacje ludzkich przeciwciał anty-RANKL i sposoby ich zastosowania

Also Published As

Publication number Publication date
EP3615065A1 (fr) 2020-03-04
US20250367115A1 (en) 2025-12-04
US20200352857A1 (en) 2020-11-12
WO2018200533A1 (fr) 2018-11-01
US12257343B2 (en) 2025-03-25

Similar Documents

Publication Publication Date Title
EP3618871A4 (fr) Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
MA49043A (fr) Formulation stable d'anticorps
EP3880688A4 (fr) Préparations et compositions d'oligosaccharides
EP3548000A4 (fr) Compositions pharmaceutiques d'atropine
MA56006A (fr) Formulations sous-cutanées d'anticorps her2
EP3840730A4 (fr) Compositions pour l'administration d'agents thérapeutiques et leurs méthodes d'utilisation et leurs procédés de préparation
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
MA54052A (fr) Formulation d'anticorps
EP3256149A4 (fr) Formulations pour administration orale d'agents actifs
EP3823978A4 (fr) Compositions d'anticorps anti-fcrn
EP3621656A4 (fr) Formulation pour l'administration d'un médicament pour les yeux
EP3518971A4 (fr) Formulations thérapeutiques d'anticorps et de protéines et leurs utilisations
EP3768250A4 (fr) Formulations pour la pulvérisation d'épinéphrine
EP3496753A4 (fr) Formulation d'anticorps anti-pd-1
MA54139A (fr) Formulation d'anticorps
IL281938A (en) Stable semaglutide compositions and uses thereof
EP3927729A4 (fr) Formulation d'anticorps thérapeutique
EP3625262A4 (fr) Immunoconjugués anti-folr1 et combinaisons d'anticorps anti-pd-1
EP3684369A4 (fr) Compositions d'anticorps a33 et leurs méthodes d'utilisation en radioimmunothérapie
MA53466A (fr) Formulation stable d'anticorps anti-osmr
EP3688033A4 (fr) Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
MA53333A (fr) Formulations pharmaceutiques d'anticorps masqués
EP3817750A4 (fr) Compositions d'associations de cannabidiol
MA49524A (fr) Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression